Ie-Ming Shih, M.D., Ph.D.

Headshot of Ie-Ming Shih
  • Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
  • Professor of Gynecology and Obstetrics

Languages: English, Chinese, Taiwanese


Endometriosis, Gynecologic/Obstetric Pathology, Pathology more

Research Interests

Cancer Pathogenesis; Cancer Diagnostics; Molecular Cancer Therapy; Molecular and Cellular Biology more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-502-7774
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-502-7774
The Johns Hopkins Hospital (Main Entrance) - Google Maps


Dr. Ie-Ming Shih is the Richard TeLinde Distinguished Professor in the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. Dr. Shih directs the inter-departmental TeLinde Gynecologic Disease Program and co-directs the Women‘s Malignancy Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions. He is the Principal Investigator of the NIH Specialized Program of Research Excellence (SPORE) of Ovarian Cancer focusing on concept-driven clinical trials and early detection of the disease. Dr. Shih's research has been continuously supported by National Institute of Health.

Dr. Shih received his M.D. from Taipei Medical University and earned his Ph.D. from the University of Pennsylvania. Dr. Shih went on completing a clinical fellowship in gynecologic pathology and a research fellowship in cancer genetics at Johns Hopkins before joining the faculty in 2001.

The scientific contributions from his team include 1) molecular characterization of different types of ovarian cancer, 2) elucidation of the origin and evolution trajectory of ovarian precancerous lesions, 3) the discovery of cancer- promoting genes that are amenable for targeting, 4) the etiology of endometriosis and 5) the pathogenesis of gestational trophoblastic neoplasm. 

Dr. Shih has published more than 360 original publications and book chapters related to basic and translational cancer research, especially in the study of gynecological malignancies. He has received the 2017 Most Influential Research Paper Award in gynecologic diseases by the Columbia Hospital Foundation, and several research awards from the Tina’s Wish Bozeman Foundation, Gray Foundation, and the Endometriosis Foundation of America to support and recognize his research works.

He sits in several advisory/editorial boards such as the World Health Organization (WHO) Nomenclature Committee for Gynecologic Neoplasms and the NCI Ovarian Task Force of Gynecologic Cancer Steering Committee. Besides his clinical, research and teaching obligations, Dr. Shih is a passionate photographer. more


  • Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
  • Director of TeLinde Gynecologic Pathology Laboratory
  • Co-Director, Womens' Malignancy Program, Sidney Kimmel Comprehensive Cancer Center
  • Professor of Gynecology and Obstetrics
  • Professor of Oncology
  • Professor of Pathology

Departments / Divisions

Centers & Institutes



  • MD; Taipei Medical University (1988)


  • Anatomic Pathology; Johns Hopkins University School of Medicine (1997)
  • Anatomic Pathology; Taipei Institute of Pathology (1989)


  • Anatomic Pathology; Johns Hopkins University School of Medicine (2000)
  • Pathology; The Wistar Institute (1994)

Board Certifications

  • American Board of Pathology (Anatomic Pathology) (1997)

Research & Publications

Research Summary

Dr. Shih's research team pursues out-of-the-box approaches at the very edges of knowledge to:

  1.  elucidate the molecular/cellular/physiological landscapes of ovarian and uterine cancers,
  2. understand the earliest events in their development and mechanisms of tumor evolution/dormancy and drug resistance,
  3. deliver promises for better prevention, detection and treatment to women who have diseases or are at an increased risk to have these cancers.,
  4. study the etiology of endometriosis and how to design a better classification system and interventions to treat endometriosis.

Please see for details about Dr. Shih's research.

Lab Website:  Richard W. TeLinde Gynecologic Pathology Research Program


Lab Website: Gynecologic Pathology Laboratory

Selected Publications

View all on PubMed

Yu Y,  Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM.  Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell, 28:82-96, 2015

Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID: 26953344

Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. ARID1A deletion in collaboration with PTEN deletion leads to ovarian tumorigenesis in mouse. J Natl Can Inst. 2014, Jun 4;106(7). pii: dju146. doi: 10.1093/jnci/dju146. Print 2014 Jul. PMCID: PMC4056776

Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded.  Am J Pathol, 186:733-747, 2016. PMID: 27012190

Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Can Inst, 104:1503-1513, 2012. PMCID: PMC3692380

Activities & Honors


  • Molecular diagnostics for malignant effusion, NCI/NIH , 2004 - 2012
  • The Roles of HBXAP Gene in Ovarian Cancer, NCI/NIH , 2008 - 2013
  • Pathogenesis of ovarian serous borderline tumors, NCI/NIH , 2007 - 2011
  • Consortium Planning Award , Department of Defense, Ovarian Cancer Research Program , 2009 - 2010
  • Nanobiosensing Method for Point Mutation Detection of Cancer, NCI/NIH , 2008 - 2010
  • Notch3 Signaling Pathway in the Ovarian Carcinoma, American Cancer Society , 2008 - 2012


  • American Association for Cancer Research
  • United States and Canadian Association of Pathologists

Professional Activities

  • NCI/NIH, Member of Cancer Molecular Pathobiology Study Section (CAMP), 2006 - 2011
  • NCI/NIH, L (12)B Cancer Diagnostic & Treatment Study Section, 2005 - 2007
  • NCI/NIH, IMAT (R21/R33) New innovative technology in cancer, 2002
  • NCI/NIH, Cancer Biomarkers Research Group, 2008
  • Ovarian cancer research program, US DoD, 2005 - 2009

Videos & Media

Recent News Articles and Media Coverage

New Center to Take Multidisciplinary Approach to Endometriosis, Johns Hopkins Gynecology & Obstetrics Newsletter (Winter 2018)

Is this you? Edit Profile
back to top button